文献速递类风湿关节炎

Torque Teno病毒定量用于监测生物制剂治疗类风湿关节炎中的免疫调节

Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis.
PubMed 文献 · Rheumatology (Oxford) · 2022-01-01

BioBio研究为多中心随机开放标签试验,纳入95例MTX应答不足的RA患者,随机接受TNFi、抗IL-6、CTLA4-Ig或抗CD20治疗并加用MTX。结果显示治疗3个月后TTV中位增加4.5×10^4 copies/ml,第3个月TTV水平与第6个月SDAI应答(P=0.03)和CDAI应答(P=0.026)相关。作者认为TTV水平在TNF、CD20和共刺激阻断后升高,并与bDMARDs临床应答相关。

要点

  • 治疗3个月后TTV中位增加4.5×10^4 copies/ml(IQR 0-7.5×10^5)。
  • 第3个月TTV水平与第6个月SDAI应答(P=0.03)和CDAI应答(P=0.026)相关。
  • 第3个月TTV截断值1.2×10^6 c/ml预测第6个月SDAI降低85%的阳性似然比为2.7。

核心结论

  • 作者认为TTV水平在TNF、CD20和共刺激阻断后升高,并与RA患者对bDMARDs的临床应答相关。

研究设计与样本

  • BioBio研究为多中心随机开放标签试验,纳入对MTX应答不足的RA患者。
  • 患者随机接受TNFi(英夫利西单抗,INF)、抗IL-6(托珠单抗,TCZ)、CTLA4-Ig(阿巴西普,ABA)或抗CD20(利妥昔单抗,RTX)并加用MTX。
  • 采用PCR定量外周血TTV,共测量95例患者(INF n=23;TCZ n=22;ABA n=27;RTX n=23)。

主要发现

  • 治疗3个月后TTV中位增加4.5×10^4 copies/ml(IQR 0-7.5×10^5)。
  • 第3个月TTV水平与第6个月SDAI应答相关(P=0.03),与第6个月CDAI应答相关(P=0.026)。
  • 第3个月TTV截断值1.2×10^6 c/ml预测第6个月SDAI降低85%的阳性似然比为2.7。

关键数值与推荐

  • 第3个月TTV截断值1.2×10^6 c/ml预测第6个月SDAI降低85%的阳性似然比为2.7。
  • 第3个月TTV水平与第6个月SDAI应答相关(P=0.03)。
  • 第3个月TTV水平与第6个月CDAI应答相关(P=0.026)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: RA patients who fail to respond to MTX can receive biologic dMARDs (bDMARDs). The Torque Teno Virus (TTV) is a potential novel candidate for monitoring of immunosuppression. We explore TTV in these patients and its association with clinical response to bDMARDs. METHODS: The BioBio Study is a multicentre randomized open-label trial, including RA patients with insufficient response to MTX. Patients were randomized to either TNFi (infliximab, INF), anti-IL-6 (tocilizumab, TCZ), CTLA4-Ig (abatacept, ABA) or anti-CD20 (rituximab, RTX) in addition to MTX. PCR was used to quantify TTV in the peripheral blood. RESULTS: TTV was measured in 95 patients (INF, n = 23; TCZ, n = 22; ABA, n = 27; RTX; n = 23). TTV increased by a median of 4.5 × 104 copies/ml [c/ml; interquartile range (IQR) 0-7.5 × 105] after 3 months. TTV levels at month 3 were associated with the Simplified Disease Activity Index (SDAI) (P = 0.03) and the Clinical Disease Activity Index (CDAI) response (P = 0.026) at month 6. A TTV cut-off level of 1.2 × 106 c/ml at month 3 had a positive likelihood ratio of 2.7 for prediction of an 85% reduction in SDAI at month 6. CONCLUSION: Our data suggest that TTV levels increase upon TNF, CD20 and costimulation blockade and are associated with the clinical response to bDMARDs in RA patients. TRIAL REGISTRATION: ClinicalTrials.gov; https://clinicaltrials.gov; NCT01638715.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Studenic P, Bond G, Kerschbaumer A, et al. Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis. Rheumatology (Oxford). 2022. PMID: 34792562. doi:10.1093/rheumatology/keab839

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。